Novo Nordisk's Pediatric Obesity Data Lands Alongside Fresh China Pressure
Published on 11/18/2026 at 13:51 | Editorial boerse-global.deNovo Nordisk released Phase III STEP Young trial results on Monday for its investigational semaglutide treatment in children with obesity, a disclosure that coincided with fresh competitive signals out of China and new real-world data on its oral Wegovy tablet.
In the six-to-under-twelve age group, body-mass index fell 17.4% among treated children, compared with a 2.2% rise in the placebo arm. The figures reflect the analysis after 68 weeks of treatment. Nearly 80% of children on Wegovy achieved a BMI reduction of at least 10%, a threshold no child in the placebo group reached. The company said the Phase III findings were also published in The New England Journal of Medicine; semaglutide was studied in STEP Young as an investigational candidate for this age cohort.
Shares slipped 0.8% on Monday to €36.70 following the study release, extending a softer run — the stock had already fallen 2.1% in the prior session.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
China Opens Its Insurance Door to Rivals
Competitive pressure is building in China, where Pfizer and Innovent Biologics are set to have their GLP-1 medicines added to the state health insurance scheme from January 1, Reuters reported on Saturday. The coverage applies to type-2 diabetes treatment, and Reuters framed the move as a new challenge for Novo Nordisk in the Chinese market.
Separately, Reuters reported Saturday on real-world data for the once-daily Wegovy tablet: patients who stayed on treatment lost an average of 6.2% of body weight within three months. The results were slated for presentation at ObesityWeek.
Regulatory Filings and a Philanthropic Pledge
On the pipeline front, Novo Nordisk submitted Etavopivat for sickle cell disease to the US Food and Drug Administration and the European Medicines Agency on November 12. The applications cover patients aged twelve and older and are directed at both regulators for that age group.
The company also committed $200 million to the World Diabetes Foundation on November 11, according to Reuters. The funding will be disbursed over ten years, with the pledge beginning in 2027.
Ad
Novo Nordisk Stock: New Analysis - 18 November
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
